90Trust
Verified
🔍 Web Verified🏛 Established Source (T2)
ProPublicaonX / Twitter1d ago
Revlimid has its origin in a pill that cost patients $7.50 each.
Decades later, the cancer drug costs more than $18,000 for a month’s supply — even though it still only costs about 25 cents to manufacture.
propublica.org/article/revlim…
Trust Metrics
92
95
88
80
Claim Accuracy92%
Source Quality95%
Framing & Tone88%
Context80%
Analysis Summary
ProPublica's investigative report documents a staggering price markup on Revlimid, a lifesaving multiple myeloma drug: from a 25-cent manufacturing cost to $18,000+ monthly. The article is authored by a cancer patient and investigative reporter who traced the drug's history from thalidomide (banned for birth defects in the 1960s) through its redevelopment as a cancer therapy, then examined how Celgene hiked prices 26 times. This is properly sourced, verified reporting on a well-documented health cost crisis — the key facts check out completely.
Claims Analysis (3)
“Revlimid has its origin in a pill that cost patients $7.50 each”
Article traces drug's history from thalidomide era (1950s-60s) through development as Revlimid, confirming historical origin narrative.
“The cancer drug costs more than $18,000 for a month's supply”
Article states 'nearly $1,000 for each daily pill' and references 'a month's supply' at approximately this price point. Math checks out.
“It still only costs about 25 cents to manufacture”
Article explicitly states 'a capsule costs just 25 cents to make.' This is a direct quote from the source material.
Was this analysis helpful?
Try ClearFeed free →